share_log

Ensysce Biosciences Q1 2024 GAAP EPS $(0.55) Beats $(0.90) Estimate, Sales $305.722K Miss $400.000K Estimate

Ensysce Biosciences Q1 2024 GAAP EPS $(0.55) Beats $(0.90) Estimate, Sales $305.722K Miss $400.000K Estimate

Ensysce Biosciences 2024年第一季度GAAP每股收益(0.55)超过预期(0.90),销售额为305.722万美元,未达到400.000万美元的预期
Benzinga ·  05/13 20:27

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.90) by 38.89 percent. The company reported quarterly sales of $305.722 thousand which missed the analyst consensus estimate of $400.000 thousand by 23.57 percent. This is a 61.28 percent decrease over sales of $789.635 thousand the same period last year.

Ensysce Biosciences(纳斯达克股票代码:ENSC)公布的季度亏损为每股0.55美元,比分析师普遍预期的0.90美元(0.90美元)高出38.89%。该公司公布的季度销售额为305,722美元,比分析师普遍预期的40万美元低23.57%。这比去年同期的789,635美元的销售额下降了61.28%。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发